Clinical trial · Interventional
A Multi-center Study on the Efficacy and Safety of AI-assisted Navigation System for Biliopancreatic EUS
A Multi-center Study on the Efficacy and Safety of Artificial Intelligence-assisted Navigation System for Biliopancreatic Endoscopic Ultrasonography
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Pancreatic cancer is one of the most lethal cancers. Survival rates vary largely depending on the stage at which it is diagnosed. EUS is considered one of the most sensitive modalities for pancreatic cancer detection. To avoid a missed diagnosis of the pancreatic cancer, the continuity and integrity of EUS needs to be ensured as much as possible. The station approach in pancreatic EUS has been established as the standard scanning procedure. Complete anatomical scanning is helpful for the identification of standard stations, and its imaging findings can assist in the diagnosis of pancreatic lesions and guide patient treatment and prognosis. But EUS is highly operator-dependent and the learning curve is steep. In this study, we constructed a deep learning-based pancreatic scanning navigation system in EUS, which can assist in identifying important anatomical structures adjacent to the pancreas in real time. In order to improve the quality of EUS and reduce the missed diagnosis of pancreatic lesions.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Artificial intelligence assistant system | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- EUS AI navigation system augmentation
- description
- The endoscopists in the experimental group will be assisted by EndoAngel, which can assist in identifying important anatomical structures adjacent to the pancreas in real time. The system is an non-invasive AI system .
- interventionNames
- Other: Artificial intelligence assistant system
- type
- NO_INTERVENTION
- label
- without EUS AI navigation system augmentation
- description
- The endoscopists in the contrpl group performs the examination routinely without special prompts.
Primary outcomes (1)
- measure
- Missed scanning rate of adjacent important anatomical structures in pancreatic endoscopic ultrasonography
- timeFrame
- Six month
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * All patients meeting the following criteria will be considered for participation in the study: 1. Male or female aged 18 or above; 2. EUS is needed to further clarify the characteristics of biliopancreatic diseases; 3. Patients able to give informed consent were eligible to participate. 4. Able and willing to comply with all study process. Exclusion Criteria: * All patients meeting the following criteria will not be considered for participation in the study: 1. Has participated in other clinical trials, signed informed consent and was in the follow-up period of other clinical trials. 2. Has participated in clinical trials of the drug and is in the elution period of the experimental drug or control drug. 3. Drug or alcohol abuse or psychological disorder in the last 5 years. 4. Patients in pregnancy or lactation. 5. A history of Upper Gastrointestinal surgery. 6. Patients with anatomical abnormalities of the upper gastrointestinal tract due to advanced neoplasia 7. Patients in whom the presence of clearly defined vital anatomical structures cannot be observed 8. Researchers believe that the patient is not suitable to participate in the trial.
References
Publications (0)
Data not yet available